Mylan (MYL): Increased Pricing Scrutiny Poses Sentiment Risk - Wells Fargo

August 24, 2016 8:21 AM EDT
Get Alerts MYL Hot Sheet
Price: $36.73 --0%

Rating Summary:
    12 Buy, 12 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 10 | Down: 6 | New: 3
Trade MYL Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Wells Fargo analyst, David Maris, reiterated his Market Perform rating on shares of Mylan (NASDAQ: MYL) and noted that Mylan is facing further scrutiny by the press, consumers, and legislators regarding price increases on EpiPen. He believes that this issue has the potential to further pressure Mylan’s share price and "investors should be very sensitive to the investment sentiment risk".

Sen. Blumenthal (D-CT) criticized Mylan and called for the FTC and the Judiciary Antitrust Subcommittee to investigate. Senator Grassley, an Iowa Republican and Chairman of the Senate Committee on the Judiciary, sent a letter to Mylan’s CEO explaining that the “substantial price increase has caused significant concern among patients” and asked Mylan to respond to questions about EpiPen pricing. This follows Sen. Amy Klobuchar (D-MN), who over the weekend called on the FTC to investigate.

For an analyst ratings summary and ratings history on Mylan click here. For more ratings news on Mylan click here.

Shares of Mylan closed at $45.62 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Litigation

Related Entities

Raising Prices, Wells Fargo, David Maris

Add Your Comment